AstraZeneca PLC (LON:AZN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is £153.33.
AZN has been the topic of several research reports. JPMorgan Chase & Co. restated an "overweight" rating on shares of AstraZeneca in a report on Thursday, January 15th. Shore Capital Group restated a "buy" rating on shares of AstraZeneca in a report on Friday, January 16th. Berenberg Bank boosted their price target on AstraZeneca from £145 to £160 and gave the stock a "buy" rating in a report on Tuesday, January 27th. Deutsche Bank Aktiengesellschaft restated a "sell" rating and set a £115 price target on shares of AstraZeneca in a report on Wednesday. Finally, Citigroup boosted their price target on AstraZeneca from £170 to £180 and gave the stock a "buy" rating in a report on Friday, April 10th.
Read Our Latest Research Report on AZN
AstraZeneca Stock Performance
AstraZeneca stock opened at £136.12 on Thursday. AstraZeneca has a 12-month low of GBX 9,651 and a 12-month high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66. The business's 50-day moving average price is £145.94 and its two-hundred day moving average price is £140.01. The stock has a market cap of £211.10 billion, a PE ratio of 20.50, a P/E/G ratio of 0.86 and a beta of 0.22.
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
